Lui H K, Lee G, Dhurandhar R, Hungate E J, Laddu A, Dietrich P, Mason D T
Am Heart J. 1983 May;105(5):722-6. doi: 10.1016/0002-8703(83)90231-4.
The antiarrhythmic efficacy of oral acebutolol, a new cardioselective beta-blocking agent, was assessed in a randomized double-blind, placebo-controlled study. Twenty-five patients with greater than or equal to 30 ventricular ectopic beats (VEB) per hour on three control ambulatory monitorings were studied. Mean VEB reduction from the control period was 35% with placebo and 45% and 50% with the use of acebutolol 200 mg and 400 mg, respectively. Eleven patients had greater than or equal to 70% reduction in VEB with acebutolol and nine of them had greater than or equal to 90 VEB reduction. Among these 11 patients, the mean VEB suppression was 51% after placebo but significantly higher following the two doses of acebutolol at 71% (p less than 0.05) and 86% (p less than 0.01). The mean reduction of paired VEB compared to placebo was 71% (p less than 0.05) and 75% (p less than 0.01) following 200 mg and 400 mg of acebutolol and only 49% after placebo. Complete suppression of paroxysmal ventricular tachycardia was also noted in five patients. Mean PR interval only increased slightly when patients took 400 mg of acebutolol, but there was no significant change in either the QRS or QTc intervals. A significant decrease in heart rate from that during control periods was noted after acebutolol. No significant adverse reactions were noted during the study. Acebutolol appears to be an effective and well-tolerated antiarrhythmic agent in the treatment of VEB and higher grades of ventricular ectopy.
在一项随机双盲、安慰剂对照研究中，对新型心脏选择性β受体阻滞剂口服醋丁洛尔的抗心律失常疗效进行了评估。研究对象为25例患者，他们在三次动态心电图监测中每小时室性早搏（VEB）≥30次。安慰剂组从对照期到研究期的平均室性早搏减少率为35%，使用200mg和400mg醋丁洛尔时分别为45%和50%。11例患者使用醋丁洛尔后室性早搏减少≥70%，其中9例减少≥90%。在这11例患者中，安慰剂治疗后平均室性早搏抑制率为51%，但在服用两剂醋丁洛尔后显著更高，分别为71%（p<0.05）和86%（p<0.01）。与安慰剂相比，服用200mg和400mg醋丁洛尔后成对室性早搏的平均减少率分别为71%（p<0.05）和75%（p<0.01），而安慰剂组仅为49%。还注意到5例患者的阵发性室性心动过速完全得到抑制。患者服用400mg醋丁洛尔时平均PR间期仅略有增加，但QRS或QTc间期均无显著变化。服用醋丁洛尔后心率较对照期显著降低。研究期间未观察到显著不良反应。醋丁洛尔似乎是治疗室性早搏和更高级别室性异位心律的一种有效且耐受性良好的抗心律失常药物。
